Literature DB >> 17519620

Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment.

Ingrid H Wolf1, Kazuo Kodama, Lorenzo Cerroni, Helmut Kerl.   

Abstract

Topical imiquimod (IQ) is an effective treatment for genital warts and various malignant tumors of the skin. IQ acts through the Toll-like receptor 7 leading to the production of cytokines and chemokines such as interferons, interleukins, and growth factors. We investigated the composition of the inflammatory cell infiltrate before, during, and after the treatment of 10 superficial cutaneous malignancies (melanoma in situ (n = 4), melanoma metastasis (n = 1), squamous cell carcinoma in situ (n = 4), and basal cell carcinoma (n = 1) with 5% IQ cream. Immunophenotyping revealed in all cases during treatment an increased population of T-lymphocytes positive for CD3, CD4 and CD8, as well as a considerable number of cytotoxic cells (TIA-1+, granzyme B+) and plasmacytoid dendritic cells (CD 123+). These findings further support previous investigations that the antitumor effects of IQ result from an enhanced cytotoxic T-cell mediated immune response and from the recruitment of plasmacytoid dendritic cells to the skin. The population of infiltrative inflammatory cells was similar in all patients irrespective of the type of tumor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17519620     DOI: 10.1097/01.dad.0000211531.33670.94

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  11 in total

Review 1.  Roles of the immune system in skin cancer.

Authors:  S Rangwala; K Y Tsai
Journal:  Br J Dermatol       Date:  2011-11       Impact factor: 9.302

2.  Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.

Authors:  Marianela Candolfi; Gwendalyn D King; Kader Yagiz; James F Curtin; Yohei Mineharu; A K M Ghulam Muhammad; David Foulad; Kurt M Kroeger; Nick Barnett; Regis Josien; Pedro R Lowenstein; Maria G Castro
Journal:  Neoplasia       Date:  2012-08       Impact factor: 5.715

3.  A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin.

Authors:  Salvatore Fiorenza; Tony J Kenna; Iain Comerford; Shaun McColl; Raymond J Steptoe; Graham R Leggatt; Ian H Frazer
Journal:  J Immunol       Date:  2012-11-09       Impact factor: 5.422

Review 4.  Toll-like receptor agonists in cancer therapy.

Authors:  Sylvia Adams
Journal:  Immunotherapy       Date:  2009-11       Impact factor: 4.196

5.  Topical Imiquimod Treatment of Lentigo Maligna.

Authors:  F Ventura; J Rocha; J C Fernandes; F Pardal; C Brito
Journal:  Case Rep Dermatol       Date:  2009-10-31

Review 6.  Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.

Authors:  Shreya Kanodia; Diane M Da Silva; W Martin Kast
Journal:  Int J Cancer       Date:  2008-01-15       Impact factor: 7.396

7.  Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.

Authors:  Douglas B Johnson; Erika K Wallender; Daniel N Cohen; Sunaina S Likhari; Jeffrey P Zwerner; Jennifer G Powers; Lisa Shinn; Mark C Kelley; Richard W Joseph; Jeffrey A Sosman
Journal:  Cancer Immunol Res       Date:  2013-12       Impact factor: 11.151

8.  The Immunomodulatory Small Molecule Imiquimod Induces Apoptosis in Devil Facial Tumour Cell Lines.

Authors:  Amanda L Patchett; Jocelyn M Darby; Cesar Tovar; A Bruce Lyons; Gregory M Woods
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

9.  Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments.

Authors:  Cristina Pellegrini; Augusto Orlandi; Gaetana Costanza; Alessandro Di Stefani; Antonella Piccioni; Antonella Di Cesare; Andrea Chiricozzi; Amedeo Ferlosio; Ketty Peris; Maria Concetta Fargnoli
Journal:  PLoS One       Date:  2017-08-22       Impact factor: 3.240

10.  Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells.

Authors:  Rachael A Clark; Susan J Huang; George F Murphy; Ilse G Mollet; Dirkjan Hijnen; Manoj Muthukuru; Carl F Schanbacher; Vonetta Edwards; Danielle M Miller; Jenny E Kim; Jo Lambert; Thomas S Kupper
Journal:  J Exp Med       Date:  2008-09-15       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.